News archive

September 2023

• Media ReleaseSep 25, 2023
  Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced…
• Media ReleaseSep 25, 2023
  Novartis confirms Sandoz Spin-off for October 4, 2023
  Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
• StatementSep 19, 2023
  Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.

  Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.

• Media ReleaseSep 18, 2023
  Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
  Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
• Media ReleaseSep 15, 2023
  Novartis shareholders approve the proposed 100% Spin-off of Sandoz
  Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off…
• Media ReleaseSep 15, 2023
  Les actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
  Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
• Media ReleaseSep 15, 2023
  Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
  Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
• Media ReleaseSep 14, 2023
  Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
  Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
• StatementSep 13, 2023
  Novartis provides support for Moroccan earthquake victims
• Featured NewsSep 13, 2023
  Novartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
• StatementSep 11, 2023
  GT005 (PPY988): Development Program in Geographic Atrophy
• Media ReleaseSep 11, 2023
  Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
  Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to…